136 related articles for article (PubMed ID: 15186594)
1. Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.
Nanni C; Castellucci P; Farsad M; Pinto C; Moretti A; Pettinato C; Marengo M; Boschi S; Franchi R; Martoni A; Monetti N; Fanti S
Cancer Biother Radiopharm; 2004 Apr; 19(2):149-54. PubMed ID: 15186594
[TBL] [Abstract][Full Text] [Related]
2. What is the best way to diagnose and stage malignant pleural mesothelioma?
Zahid I; Sharif S; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 Feb; 12(2):254-9. PubMed ID: 21044972
[TBL] [Abstract][Full Text] [Related]
3. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
Abe Y; Tamura K; Sakata I; Ishida J; Ozeki Y; Tamura A; Uematsu K; Sakai H; Goya T; Kanazawa M; Machida K
Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
[TBL] [Abstract][Full Text] [Related]
4. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
[TBL] [Abstract][Full Text] [Related]
5. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
Sharif S; Zahid I; Routledge T; Scarci M
Interact Cardiovasc Thorac Surg; 2011 May; 12(5):806-11. PubMed ID: 21266493
[TBL] [Abstract][Full Text] [Related]
6. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
Pilling J; Dartnell JA; Lang-Lazdunski L
Thorac Cardiovasc Surg; 2010 Jun; 58(4):215-9. PubMed ID: 20514576
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of 18F-FDG standard uptake value by integrated PET/CT in the staging of malignant pleural mesothelioma.
Genestreti G; Moretti A; Piciucchi S; Tiseo M; Bersanelli M; Scarlattei M; Scarpi E; Dubini A; Matteucci F; Sanna S
Technol Cancer Res Treat; 2012 Apr; 11(2):163-7. PubMed ID: 22335410
[TBL] [Abstract][Full Text] [Related]
8. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
[TBL] [Abstract][Full Text] [Related]
9. Malignant pleural mesothelioma presenting as low back pain: diagnosed by bone scan coordinating with F-18 FDG PET/CT.
Huang YC; Tu DG; Wu JD; Lee MY
Spine (Phila Pa 1976); 2009 Oct; 34(21):E780-3. PubMed ID: 19934799
[TBL] [Abstract][Full Text] [Related]
10. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
Gerbaudo VH; Mamede M; Trotman-Dickenson B; Hatabu H; Sugarbaker DJ
Eur J Nucl Med Mol Imaging; 2011 May; 38(5):810-21. PubMed ID: 21210110
[TBL] [Abstract][Full Text] [Related]
11. Loco-regional staging of malignant pleural mesothelioma by integrated
Murphy DJ; Mak SM; Mallia A; Jeljeli S; Stirling JJ; Goh V; Bille A; Cook GJR
Eur J Radiol; 2019 Jun; 115():46-52. PubMed ID: 31084758
[TBL] [Abstract][Full Text] [Related]
12. Additional value of hybrid PET/CT fusion imaging vs. conventional CT scan alone in the staging and management of patients with malignant pleural mesothelioma.
Ambrosini V; Rubello D; Nanni C; Farsad M; Castellucci P; Franchi R; Fabbri M; Rampin L; Crepaldi G; Al-Nahhas A; Fanti S
Nucl Med Rev Cent East Eur; 2005; 8(2):111-5. PubMed ID: 16437396
[TBL] [Abstract][Full Text] [Related]
13. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
[TBL] [Abstract][Full Text] [Related]
14. Morphologic and functional imaging of malignant pleural mesothelioma.
Yamamuro M; Gerbaudo VH; Gill RR; Jacobson FL; Sugarbaker DJ; Hatabu H
Eur J Radiol; 2007 Dec; 64(3):356-66. PubMed ID: 17954021
[TBL] [Abstract][Full Text] [Related]
15. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
Wilcox BE; Subramaniam RM; Peller PJ; Aughenbaugh GL; Nichols Iii FC; Aubry MC; Jett JR
Clin Lung Cancer; 2009 Jul; 10(4):244-8. PubMed ID: 19632941
[TBL] [Abstract][Full Text] [Related]
16. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
[TBL] [Abstract][Full Text] [Related]
17. Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.
Basu S; Saboury B; Torigian DA; Alavi A
Mol Imaging Biol; 2011 Oct; 13(5):801-11. PubMed ID: 21136185
[TBL] [Abstract][Full Text] [Related]
18.
Elliott HS; Metser U; de Perrot M; Cho J; Bradbury P; Veit-Haibach P; Hussey D; Noam T
Br J Radiol; 2018 Jun; 91(1086):20170814. PubMed ID: 29498536
[TBL] [Abstract][Full Text] [Related]
19. Dual time point FDG PET for evaluation of malignant pleural mesothelioma.
Yamamoto Y; Kameyama R; Togami T; Kimura N; Ishikawa S; Yamamoto Y; Nishiyama Y
Nucl Med Commun; 2009 Jan; 30(1):25-9. PubMed ID: 19306511
[TBL] [Abstract][Full Text] [Related]
20. Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
Abakay A; Komek H; Abakay O; Palanci Y; Ekici F; Tekbas G; Tanrikulu AC
Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1233-41. PubMed ID: 23690193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
